Citations per year, relative to Chris Fellner Chris Fellner (= 1×)
peers
Chuang Yuan
Countries citing papers authored by Chris Fellner
Since
Specialization
Citations
This map shows the geographic impact of Chris Fellner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Fellner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Fellner more than expected).
This network shows the impact of papers produced by Chris Fellner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Fellner. The network helps show where Chris Fellner may publish in the future.
Co-authorship network of co-authors of Chris Fellner
This figure shows the co-authorship network connecting the top 25 collaborators of Chris Fellner.
A scholar is included among the top collaborators of Chris Fellner based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Chris Fellner. Chris Fellner is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Bennett, Lunawati L. & Chris Fellner. (2018). Pharmacotherapy of Gaucher Disease: Current and Future Options.. PubMed. 43(5). 274–309.19 indexed citations
Fellner, Chris. (2017). Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer.. PubMed. 42(4). 262–265.9 indexed citations
4.
Fellner, Chris. (2017). Immunotherapies in Late-Stage Development for Patients With Severe SLE and/or Lupus Nephritis.. PubMed. 42(6). 394–397.1 indexed citations
5.
Fellner, Chris. (2016). Zika in America: The Year in Review.. PubMed. 41(12). 778–791.4 indexed citations
6.
Fellner, Chris. (2016). Companies Take Aim at MRSA Infections.. PubMed. 41(2). 126–8.3 indexed citations
7.
Fellner, Chris. (2016). Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.. PubMed. 41(8). 523–5.2 indexed citations
8.
Fellner, Chris. (2016). More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis.. PubMed. 41(6). 388–90.2 indexed citations
Fellner, Chris. (2016). Biologics Will Pump Up the Vasculitis Market.. PubMed. 41(4). 258–60.2 indexed citations
11.
Fellner, Chris, et al.. (2015). Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.. PubMed. 40(7). 451–62.60 indexed citations
12.
Fellner, Chris, et al.. (2015). A review of 2014 cancer drug approvals, with a look at 2015 and beyond.. PubMed. 40(3). 191–205.16 indexed citations
Gregory, Philip J. & Chris Fellner. (2014). Dietary supplements as disease-modifying treatments in osteoarthritis: a critical appraisal.. PubMed. 39(6). 436–52.6 indexed citations
15.
Pettit, Rebecca S. & Chris Fellner. (2014). CFTR Modulators for the Treatment of Cystic Fibrosis.. PubMed. 39(7). 500–11.56 indexed citations
Fellner, Chris. (2012). Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.. PubMed. 37(9). 503–30.110 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.